TITLE

ASCO/ONS create standards for chemotherapy administration

PUB. DATE
November 2009
SOURCE
Hem/Onc Today;11/10/2009, Vol. 10 Issue 21, p34
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the standards released by the American Society of Clinical Oncology and the Oncology Nursing Society for the administration of chemotherapy to adult patients in the outpatient setting.
ACCESSION #
44861406

 

Related Articles

  • Reality Check.  // Newsweek (Pacific Edition);6/25/2007 (Pacific Edition), Vol. 150 Issue 1, p7 

    The article focuses on the effects of chemotherapy on the human brain. It mentions "chemo brain" as a fogginess in thought processes as a result of chemotherapy. It states that the American Society of Clinical Oncology believes this condition can be treated with the drug Modafinil, which was...

  • Reality Check.  // Newsweek (Atlantic Edition);6/25/2007 (Atlantic Edition), Vol. 150 Issue 1, p7 

    The article focuses on the effects of chemotherapy on the human brain. It mentions "chemo brain" as a fogginess in thought processes as a result of chemotherapy. It states that the American Society of Clinical Oncology believes this condition can be treated with the drug Modafinil, which was...

  • Chemotherapy benefits nearly all early breast cancer patients. McNeil, Caroline // JNCI: Journal of the National Cancer Institute;06/18/97, Vol. 89 Issue 12, p838 

    Focuses on the benefits of chemotherapy among breast cancer patients discussed during the American Society of Clinical Oncology in Denver, Colorado. Implications of the definitive findings of breast cancer; Comparison between groups of post-operative treatment of standard chemotherapy regimen. ...

  • High-Dose Chemo and Breast Cancer: Early Results Spark Debate. Arnold, Katherine // JNCI: Journal of the National Cancer Institute;06/16/99, Vol. 91 Issue 12, p992 

    Discusses the results of the high-dose chemotherapy clinical trials on breast cancer presented in Atlanta at the 35th Annual Meeting of the American Society of Clinical Oncology in May 1999. Implication of the results; Differences among the five trials; Concerns arising from the preliminary...

  • New ASCO guidelines change recommendations for amifostine, add section on palifermin. Harris, Jason // Hem/Onc Today;12/25/2008, Vol. 9 Issue 23, p52 

    The article focuses on the new American Society of Clinical Oncology (ASCO) guidelines which change recommendations for amifostine for the prevention of several potential adverse effects in chemotherapy and radiation therapy. The Society also created guidelines on palifermin, a recombinant...

  • T-DM1 Slows Breast Cancer, With Fewer Side Effects. Breindl, Anette // BioWorld Today;6/5/2012, Vol. 23 Issue 108, p2 

    The article reports that Genentech Inc. and ImmunoGen Inc. have presented data from the Phase III Emilia trial of T-DMI antibody drug at the plenary session of the 2012 annual meeting of the American Society of Clinical Oncology (ASCO). The trastuzumab emtansine is developed to treat locally...

  • Melanoma Trial Results Lead to 'Unprecedented' Options.  // Bioworld Week;6/13/2011, Vol. 19 Issue 24, p1 

    The article focuses on the results of the clinical trials for melanoma drugs such as Vemurafenib and Yervoy which were presented during the 47th annual meeting of the American Society of Clinical Oncology (ASCO). It states that Vemurafenib was found to reduce the risk of tumour progression and...

  • Shouting 'Cure!'--or Whispering 'Hope'--in a Crowded Cancer Ward. Healy, Bernadine P. // Journal of Women's Health;Jun98, Vol. 7 Issue 5, p489 

    The article discusses the developments in the cure and prevention of cancer and also emphasizes on the hope attached to it by the people of the United States. Reports on endostatin and angiostatin surrounded the media. It focused on curing cancer in 2 years. The start-up company that was...

  • The new front line treatment for malignant pleural mesothelioma? Steele, J. P. C. // Thorax;Feb2003, Vol. 58 Issue 2, p96 

    Malignant pleural mesothelioma has become a mainstream cancer. This is partly due to the increasing incidence, but is also a result of the advances being made in its treatment. This summer the American Society of Clinical Oncology Annual Meeting plenary session included a clinical research paper...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics